Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

completed125%
active_not_recruiting125%
unknown250%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingphase_1

Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

NCT06545110
completed

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

NCT05302947
unknownphase_2

Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

NCT04346147
unknownphase_2

Baricitinib Compared to Standard Therapy in Patients With COVID-19

NCT04393051

Clinical Trials (4)

Showing 4 of 4 trials
NCT06545110Phase 1

Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

Active Not Recruiting
NCT05302947

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Completed
NCT04346147Phase 2

Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Unknown
NCT04393051Phase 2

Baricitinib Compared to Standard Therapy in Patients With COVID-19

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4